{"transactions":[{"id":1738838,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-11-16T16:12:01.000Z","date":"2023-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":53122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 28, 2023, Mallinckrodt plc (the \"Company\") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the \"Irish High Court\") seeking the appointment of an examiner (the \"Examiner\") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the \"Plan\"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the \"Scheme\"). On November 14, 2023 (the \"Effective Date\"), the Plan and the Scheme became effective and the Company emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of the Company's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-119106","document":"tm2330745-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465923119106/tm2330745-16_4seq1.xml","form_type":"4"}},{"id":1841908,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-29T18:50:05.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26277,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc (\"Mallinckrodt\") in connection with the Board of Directors (the \"Board\") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the \"Compensation Changes\"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (the \"RSUs\") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc (\"Mallinckrodt\") in connection with the Board of Directors (the \"Board\") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the \"Compensation Changes\"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The restricted stock units (the \"RSUs\") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc (\"Mallinckrodt\") in connection with the Board of Directors (the \"Board\") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the \"Compensation Changes\"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023."}],"balance_after":53122,"source":{"system":"sec-edgar","filing":"0001104659-23-076465","document":"tm2320181-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465923076465/tm2320181-8_4seq1.xml","form_type":"4"}},{"id":1841907,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-29T18:50:05.000Z","date":"2023-06-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":3154,"price":1.28,"value":4037.12,"ownership":{"direct":true},"balance_after":79399,"source":{"system":"sec-edgar","filing":"0001104659-23-076465","document":"tm2320181-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465923076465/tm2320181-8_4seq1.xml","form_type":"4"}},{"id":1949833,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-03-16T16:05:46.000Z","date":"2023-03-15","kind":"purchase","acquired":true,"shares":15000,"price":8.5437,"value":128155.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.47 to $8.67, inclusive."}],"balance_after":82553,"source":{"system":"sec-edgar","filing":"0001104659-23-033302","document":"tm239775-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465923033302/tm239775-2_4seq1.xml","form_type":"4"}},{"id":1949832,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-03-16T16:05:46.000Z","date":"2023-03-14","kind":"purchase","acquired":true,"shares":15000,"price":8.4213,"value":126319.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.23 to $8.75, inclusive. The reporting person undertakes to provide to Mallinckrodt plc, any security holder of Mallinckrodt plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 and 2 to this Form 4."}],"balance_after":67553,"source":{"system":"sec-edgar","filing":"0001104659-23-033302","document":"tm239775-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465923033302/tm239775-2_4seq1.xml","form_type":"4"}},{"id":2062102,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-01-05T18:01:24.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":26277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported ordinary shares represent restricted stock units (\"RSUs\"), which will be settled in an equal number of MNK ordinary shares and will vest ratably on each of the first two anniversaries of MNK's emergence from Chapter 11 proceedings on June 16, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 26,277 newly awarded RSUs and 26,276 RSUs previously reported in Table II."}],"balance_after":52553,"source":{"system":"sec-edgar","filing":"0001104659-23-001541","document":"tm231710-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465923001541/tm231710-3_4seq1.xml","form_type":"4"}},{"id":2159213,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-09-14T21:16:17.000Z","date":"2022-08-16","kind":"disposition_to_issuer","acquired":false,"shares":22533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As previously disclosed, on August 16, 2022, James R. Sulat agreed to relinquish 22,533 of the restricted stock units (\"RSUs\") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the \"MIP\"). Mallinckrodt plc (\"Mallinckrodt\") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. Sulat 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As previously disclosed, on August 16, 2022, James R. Sulat agreed to relinquish 22,533 of the restricted stock units (\"RSUs\") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the \"MIP\"). Mallinckrodt plc (\"Mallinckrodt\") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. Sulat 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As previously disclosed, on August 16, 2022, James R. Sulat agreed to relinquish 22,533 of the restricted stock units (\"RSUs\") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the \"MIP\"). Mallinckrodt plc (\"Mallinckrodt\") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. Sulat 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence."}],"balance_after":26276,"derivative":{"underlying":"Ordinary Shares","underlying_shares":22533},"source":{"system":"sec-edgar","filing":"0001104659-22-100151","document":"tm2225913-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465922100151/tm2225913-4_4seq1.xml","form_type":"4"}},{"id":2211592,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-07-06T21:08:29.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":48809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock."}],"balance_after":48809,"derivative":{"underlying":"Ordinary Shares","underlying_shares":48809},"source":{"system":"sec-edgar","filing":"0000899243-22-025533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000089924322025533/doc4.xml","form_type":"4"}},{"id":2231289,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-06-15T16:19:43.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.126,"expiration_date":"2032-06-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-036945","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000120919122036945/doc4.xml","form_type":"4"}},{"id":2554160,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-10-01T08:14:36.000Z","date":"2021-09-27","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Plan. 1/3 of the option vested on the grant date and the remainder of the option shall vest equally on each of the first 24 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable."}],"balance_after":250000,"derivative":{"exercise_price":0.1028,"expiration_date":"2031-09-26","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-21-121634","document":"tm2129012d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465921121634/tm2129012d3_4.xml","form_type":"4"}},{"id":2554159,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-10-01T08:14:36.000Z","date":"2021-09-27","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the \"Plan\"). The option shall vest equally on each of the first 36 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable."}],"balance_after":250000,"derivative":{"exercise_price":0.1028,"expiration_date":"2031-09-26","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-21-121634","document":"tm2129012d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465921121634/tm2129012d3_4.xml","form_type":"4"}},{"id":2680678,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-04T17:20:49.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.71,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-038326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000120919121038326/doc4.xml","form_type":"4"}},{"id":2919821,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-05T16:46:55.000Z","date":"2021-01-02","kind":"grant","acquired":true,"shares":43386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 36 substantially equal monthly installments from the vesting commencement date of January 2, 2021, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":43386,"derivative":{"exercise_price":1.82,"expiration_date":"2031-01-01","underlying":"Common Stock","underlying_shares":43386},"source":{"system":"sec-edgar","filing":"0001209191-21-001201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000120919121001201/doc4.xml","form_type":"4"}},{"id":2978806,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":21289,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21289},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978805,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":17326,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17326},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978804,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":7543,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7543},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978803,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":10110,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10110},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978802,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":12787,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12787},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978801,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":3575,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3575},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978800,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":3800,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3800},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978799,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":317,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978798,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":2978797,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-17T15:45:16.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":35090,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-126327","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126327/a4.xml","form_type":"4"}},{"id":3101765,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series J Warrant (right to buy)","published_at":"2020-06-23T07:59:47.000Z","date":"2020-06-22","kind":"purchase","acquired":true,"shares":340910,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Series J Warrants issued upon the exercise of and payment for all Series D warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Held indirectly by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's immediately family are the beneficiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's immediately family are the beneficiaries."}],"balance_after":340910,"derivative":{"exercise_price":0.25,"exercise_date":"2020-06-22","expiration_date":"2021-06-22","underlying":"Common Stock","underlying_shares":340910},"source":{"system":"sec-edgar","filing":"0001104659-20-075860","document":"tm2023170-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465920075860/tm2023170-1_4.xml","form_type":"4"}},{"id":3101764,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Warrant (right to buy)","published_at":"2020-06-23T07:59:47.000Z","date":"2020-06-22","kind":"other","acquired":true,"shares":454546,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Of the Shares purchased, all are from the exercise of Series D Warrants originally issued as part of a private placement that was concluded on July 2, 2015 and originally issued with an exercise price of $0.25.  On June 3, 2020, among other items, the exercise price of the Series D Warrants was amended to $0.18."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Held indirectly by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's immediately family are the beneficiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's immediately family are the beneficiaries."}],"balance_after":0,"derivative":{"exercise_price":0.18,"exercise_date":"2015-06-30","expiration_date":"2020-06-30","underlying":"Common Stock","underlying_shares":454546},"source":{"system":"sec-edgar","filing":"0001104659-20-075860","document":"tm2023170-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465920075860/tm2023170-1_4.xml","form_type":"4"}},{"id":3101763,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T07:59:47.000Z","date":"2020-06-22","kind":"other","acquired":true,"shares":454546,"price":81818.28,"value":37190171900.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Of the Shares purchased, all are from the exercise of Series D Warrants originally issued as part of a private placement that was concluded on July 2, 2015 and originally issued with an exercise price of $0.25.  On June 3, 2020, among other items, the exercise price of the Series D Warrants was amended to $0.18."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Excludes (a) 41,666 shares of our Common Stock held by the Brenna Keyes Sulat Irrevocable Trust; and, (b) 41,666 shares of our Common Stock held by the Nathaniel Keyes Sulat Irrevocable Trust.  Mr. Sulat is a co-trustee of each of the Trusts along with his wife."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Held indirectly by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's immediately family are the beneficiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's immediately family are the beneficiaries."}],"balance_after":1376813,"source":{"system":"sec-edgar","filing":"0001104659-20-075860","document":"tm2023170-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465920075860/tm2023170-1_4.xml","form_type":"4"}},{"id":3122737,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-04T16:49:32.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":21289,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders."}],"balance_after":21289,"derivative":{"exercise_price":8.52,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":21289},"source":{"system":"sec-edgar","filing":"0000792977-20-000059","document":"wf-form4_159130375405708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000059/wf-form4_159130375405708.xml","form_type":"4"}},{"id":3122736,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T16:49:32.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":10269,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) a Change in Control (as defined in the Issuer's Non-Employee Directors' Deferred Compensation Program) of the Issuer and (b) the date of the director's separation from service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":35090,"source":{"system":"sec-edgar","filing":"0000792977-20-000059","document":"wf-form4_159130375405708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000059/wf-form4_159130375405708.xml","form_type":"4"}},{"id":3332328,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-23T08:33:34.000Z","date":"2019-12-20","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Of the Shares subject to the Option, 1/12 shall vest on each of the next twelve (12) monthly anniversaries of the Vesting Commencement Date. In the event of a Change of Control (as such term is defined in the Plan) all Options subject to this grant will immediately vest."}],"balance_after":300000,"derivative":{"exercise_price":0.2292,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001104659-19-075321","document":"tm1926824-3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000110465919075321/tm1926824-3_4.xml","form_type":"4"}},{"id":3481104,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-06-21T16:14:04.000Z","date":"2019-06-20","kind":"exercise","acquired":false,"shares":4356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4356},"source":{"system":"sec-edgar","filing":"0001179110-19-008019","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019008019/edgar.xml","form_type":"4"}},{"id":3481103,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-21T16:14:04.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan.  The stock option will vest and become exercisable on the first anniversary of the grant date."}],"balance_after":25000,"derivative":{"exercise_price":12.64,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-19-008019","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019008019/edgar.xml","form_type":"4"}},{"id":3481102,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T16:14:04.000Z","date":"2019-06-20","kind":"exercise","acquired":true,"shares":4356,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":54090,"source":{"system":"sec-edgar","filing":"0001179110-19-008019","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019008019/edgar.xml","form_type":"4"}},{"id":3508555,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-29T16:12:48.000Z","date":"2019-05-24","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":8.85,"exercise_date":"2010-06-11","expiration_date":"2019-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-19-006769","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019006769/edgar.xml","form_type":"4"}},{"id":3508554,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-29T16:12:48.000Z","date":"2019-05-24","kind":"exercise","acquired":true,"shares":10000,"price":8.85,"value":88500.0,"ownership":{"direct":true},"balance_after":49734,"source":{"system":"sec-edgar","filing":"0001179110-19-006769","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019006769/edgar.xml","form_type":"4"}},{"id":3519544,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-20T07:31:38.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":17326,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders."}],"balance_after":17326,"derivative":{"exercise_price":10.78,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":17326},"source":{"system":"sec-edgar","filing":"0000792977-19-000106","document":"wf-form4_155835188371234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000106/wf-form4_155835188371234.xml","form_type":"4"}},{"id":3519543,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-20T07:31:38.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":8116,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":24821,"source":{"system":"sec-edgar","filing":"0000792977-19-000106","document":"wf-form4_155835188371234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000106/wf-form4_155835188371234.xml","form_type":"4"}},{"id":3820474,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-10T16:48:40.000Z","date":"2018-09-06","kind":"exercise","acquired":false,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13500,"derivative":{"exercise_price":14.79,"exercise_date":"2011-09-12","expiration_date":"2018-09-12","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001179110-18-011251","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911018011251/edgar.xml","form_type":"4"}},{"id":3820473,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-10T16:48:40.000Z","date":"2018-09-06","kind":"exercise","acquired":true,"shares":13500,"price":14.79,"value":199665.0,"ownership":{"direct":true},"balance_after":39734,"source":{"system":"sec-edgar","filing":"0001179110-18-011251","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911018011251/edgar.xml","form_type":"4"}},{"id":3863537,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-20T12:05:22.000Z","date":"2018-07-19","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Of the Shares subject to this Grant, 1/12th shall vest on each of the next twelve (12) monthly anniversaries of the vesting commencement date."}],"balance_after":110000,"derivative":{"exercise_price":0.425,"expiration_date":"2028-07-18","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001144204-18-039096","document":"tv498880_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000114420418039096/tv498880_4.xml","form_type":"4"}},{"id":3863536,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T12:05:22.000Z","date":"2018-07-19","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Of the Shares subject to this grant, all are issued pursuant to the 2013 Stock Incentive Plan (the \"Plan\") and 100% shall fully vest on the second anniversary of the date of grant.  In addition, in the event of a Change of Control (as such term is defined in the Plan) 100% of grant will immediately vest."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Excludes (i) 922,267 shares owned by the Keyes Sulat Revocable Trust; (ii) 41,666 shares owned by the Brenna Keyes Sulat Irrevocable Trust; and (iii) 41,666 shares owned by the Nathaniel Keyes Sulat Irrevocable Trust. Mr. Sulat and his spouse are the co-trustees of each trust, and the members of Mr. Sulat's family are the beneficiaries."}],"balance_after":370000,"source":{"system":"sec-edgar","filing":"0001144204-18-039096","document":"tv498880_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000114420418039096/tv498880_4.xml","form_type":"4"}},{"id":3865115,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-18T14:33:16.000Z","date":"2018-07-16","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33.3% of the shares subject to the option vested on July 1, 2014, and 1/24th of the remaining unvested shares vest monthly thereafter, with all shares underlying the option subject to automatic acceleration of vesting upon a Corporate Transaction or Change in Control (as such terms are defined under the Issuer's 2013 Stock Incentive Plan). To the extent vested, the reporting person must exercise the stock option during the 2018 calendar year, unless the Issuer undergoes a Corporate Transaction or Change in Control which also constitutes a \"change in the ownership or effective control, or in the ownership of a substantial portion of the assets\" (within the meaning of Code Section 409A) of the Company in a calendar year earlier than 2018, in which case the option must be exercised during such earlier calendar year."}],"balance_after":0,"derivative":{"exercise_price":0.37,"expiration_date":"2023-06-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001144204-18-038834","document":"tv498784_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000114420418038834/tv498784_4.xml","form_type":"4"}},{"id":3865114,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-18T14:33:16.000Z","date":"2018-07-16","kind":"exercise","acquired":true,"shares":30000,"price":0.37,"value":11100.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Excludes (i) 922,267 shares owned by the Keyes Sulat Revocable Trust; (ii) 41,666 shares owned by the Brenna Keyes Sulat Irrevocable Trust; and (iii) 41,666 shares owned by the Nathaniel Keyes Sulat Irrevocable Trust.  Mr. Sulat and his spouse are the co-trustees of each trust, and the members of Mr. Sulat's family are the beneficiaries."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Excludes (i) 922,267 shares owned by the Keyes Sulat Revocable Trust; (ii) 41,666 shares owned by the Brenna Keyes Sulat Irrevocable Trust; and (iii) 41,666 shares owned by the Nathaniel Keyes Sulat Irrevocable Trust.  Mr. Sulat and his spouse are the co-trustees of each trust, and the members of Mr. Sulat's family are the beneficiaries."}],"balance_after":260000,"source":{"system":"sec-edgar","filing":"0001144204-18-038834","document":"tv498784_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000114420418038834/tv498784_4.xml","form_type":"4"}},{"id":3884812,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-06-22T17:58:43.000Z","date":"2018-06-20","kind":"exercise","acquired":false,"shares":5734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5734},"source":{"system":"sec-edgar","filing":"0001179110-18-008968","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911018008968/edgar.xml","form_type":"4"}},{"id":3884811,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-06-22T17:58:43.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":4356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of MNTA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Mr. Sulat's continued service to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Mr. Sulat's continued service to the Company."}],"balance_after":4356,"derivative":{"underlying":"Common Stock","underlying_shares":4356},"source":{"system":"sec-edgar","filing":"0001179110-18-008968","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911018008968/edgar.xml","form_type":"4"}},{"id":3884810,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T17:58:43.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":8855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan.  The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Mr. Sulat's continued service to the Company."}],"balance_after":8855,"derivative":{"exercise_price":22.3,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":8855},"source":{"system":"sec-edgar","filing":"0001179110-18-008968","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911018008968/edgar.xml","form_type":"4"}},{"id":3884809,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-22T17:58:43.000Z","date":"2018-06-20","kind":"exercise","acquired":true,"shares":5734,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":26234,"source":{"system":"sec-edgar","filing":"0001179110-18-008968","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911018008968/edgar.xml","form_type":"4"}},{"id":3900923,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-08T16:10:13.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":7543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders."}],"balance_after":7543,"derivative":{"exercise_price":24.45,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":7543},"source":{"system":"sec-edgar","filing":"0000792977-18-000039","document":"wf-form4_152848859691779.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297718000039/wf-form4_152848859691779.xml","form_type":"4"}},{"id":3900922,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T16:10:13.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":3578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the \"Plan\") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders, however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":16705,"source":{"system":"sec-edgar","filing":"0000792977-18-000039","document":"wf-form4_152848859691779.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297718000039/wf-form4_152848859691779.xml","form_type":"4"}},{"id":4274395,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-06-22T16:18:18.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":5734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of MNTA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Mr. Sulat's continued service to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Mr. Sulat's continued service to the Company."}],"balance_after":5734,"derivative":{"underlying":"Common Stock","underlying_shares":5734},"source":{"system":"sec-edgar","filing":"0001179110-17-009457","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911017009457/edgar.xml","form_type":"4"}},{"id":4274394,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-22T16:18:18.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":11207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan.  The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Mr. Sulat's continued service to the Company."}],"balance_after":11207,"derivative":{"exercise_price":17.2,"expiration_date":"2027-06-20","underlying":"Common Stock","underlying_shares":11207},"source":{"system":"sec-edgar","filing":"0001179110-17-009457","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911017009457/edgar.xml","form_type":"4"}},{"id":4310952,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-22T19:14:24.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":10110,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders."}],"balance_after":10110,"derivative":{"exercise_price":19.25,"expiration_date":"2027-05-18","underlying":"Common Stock","underlying_shares":10110},"source":{"system":"sec-edgar","filing":"0001179110-17-007792","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017007792/edgar.xml","form_type":"4"}},{"id":4310951,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-22T19:14:24.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":4545,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan (the \"Plan\") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders, however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":13127,"source":{"system":"sec-edgar","filing":"0001179110-17-007792","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017007792/edgar.xml","form_type":"4"}},{"id":4466125,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-02-06T11:30:17.000Z","date":"2017-02-03","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Of the Shares subject to this Grant, 1/12th shall vest on each of the next twelve (12) monthly anniversaries of the vesting commencement date."}],"balance_after":200000,"derivative":{"exercise_price":0.65,"expiration_date":"2027-02-02","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001144204-17-006095","document":"v458451_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000114420417006095/v458451_4.xml","form_type":"4"}},{"id":4466124,"issuer":{"id":109849,"kind":"organization","name":"Arch Therapeutics, Inc.","symbol":"ARTH"},"owners":[{"id":108185,"kind":"person","name":"SULAT JAMES R","position":1,"cik":"0001229448","reported_name":"SULAT JAMES R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-06T11:30:17.000Z","date":"2017-02-03","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Of the Shares subject to this grant, all are issued pursuant to the 2013 Stock Incentive Plan (the \"Plan\") and 100% shall fully vest on the second anniversary of the date of grant. In addition, in the event of a Change of Control (as such term is defined in the Plan) 100% of grant will immediately vest."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Excludes 838,934 shares owned by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's family are the beneficiaries."}],"balance_after":230000,"source":{"system":"sec-edgar","filing":"0001144204-17-006095","document":"v458451_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229448/000114420417006095/v458451_4.xml","form_type":"4"}}]}